Home
MRUS
MRUS News

Latest Merus N.V. (MRUS) News on September 5, 2025

Why Merus N.V. (MRUS) Crashed On Wednesday

Insider Monkey

3 months ago

Why Merus N.V. (MRUS) Crashed On Wednesday

MT Newswires

3 months ago

Sector Update: Health Care Stocks Mixed Premarket Wednesday

MT Newswires

3 months ago

Merus Prices $300 Million Stock Offering

Merus N.V. Announces Pricing of Public Offering of Common Shares

GlobeNewswire

3 months ago

Merus N.V. Announces Pricing of Public Offering of Common Shares

MT Newswires

3 months ago

Merus Plans Public Share Offering

Merus N.V. Announces Proposed Public Offering of Common Shares

GlobeNewswire

3 months ago

Merus N.V. Announces Proposed Public Offering of Common Shares

ASCO 2025: Merus wins in head-to-head with Bicara for head and neck cancer

Clinical Trials Arena

3 months ago

ASCO 2025: Merus wins in head-to-head with Bicara for head and neck cancer

Merus to Present at Upcoming Investor Conferences

GlobeNewswire

3 months ago

Merus to Present at Upcoming Investor Conferences

BofA Maintains Buy Rating on Merus (MRUS), Lifts PT

Insider Monkey

3 months ago

BofA Maintains Buy Rating on Merus (MRUS), Lifts PT

Merus (MRUS) Price Target Raised at BMO After Positive Phase 2 Data

Insider Monkey

3 months ago

Merus (MRUS) Price Target Raised at BMO After Positive Phase 2 Data

Merus updates on Petosemtamab+Pembrolizumab data in HNSCC

TipRanks

3 months ago

Merus updates on Petosemtamab+Pembrolizumab data in HNSCC

MT Newswires

3 months ago

Top Midday Gainers

MT Newswires

3 months ago

Update: Merus Shares Surge After Revealing Favorable Interim Cancer Trial Data

MT Newswires

3 months ago

Merus' Cancer Treatment Delivers 'Flawless Victory' in Phase 2 Update, Truist Says

Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics

Investor's Business Daily

3 months ago

Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics

MT Newswires

3 months ago

Sector Update: Health Care

MT Newswires

3 months ago

Merus Says Interim Cancer Trial Data Show 'Robust' Efficacy, Durability; Shares Jump Premarket

Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC

GlobeNewswire

3 months ago

Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC

Merus Announces the Journal Publication of Petosemtamab Mechanism of Action

GlobeNewswire

4 months ago

Merus Announces the Journal Publication of Petosemtamab Mechanism of Action

Merus First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

4 months ago

Merus First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Merus N.V. (MRUS): Among the Best Cancer Stocks to Invest in for Long-Term Gain

Insider Monkey

4 months ago

Merus N.V. (MRUS): Among the Best Cancer Stocks to Invest in for Long-Term Gain

Merus to Present at BofA Securities 2025 Health Care Conference

GlobeNewswire

4 months ago

Merus to Present at BofA Securities 2025 Health Care Conference

Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates

Zacks

4 months ago

Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates

Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update

GlobeNewswire

4 months ago

Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update

Earnings Preview: Merus N.V. (MRUS) Q1 Earnings Expected to Decline

Zacks

4 months ago

Earnings Preview: Merus N.V. (MRUS) Q1 Earnings Expected to Decline

Merus Will Have a Best-in-Class Treatment for Head and Neck Cancer, Analysts Say

Barrons.com

4 months ago

Merus Will Have a Best-in-Class Treatment for Head and Neck Cancer, Analysts Say

Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting

GlobeNewswire

4 months ago

Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting

Is Merus (NASDAQ:MRUS) the Best High Short Interest Stock to Buy Now?

Insider Monkey

5 months ago

Is Merus (NASDAQ:MRUS) the Best High Short Interest Stock to Buy Now?

Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength?

Zacks

5 months ago

Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength?

Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

GlobeNewswire

5 months ago

Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Analyst Forecasts Just Became More Bearish On Merus N.V. (NASDAQ:MRUS)

Simply Wall St.

6 months ago

Analyst Forecasts Just Became More Bearish On Merus N.V. (NASDAQ:MRUS)

Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates

Zacks

6 months ago

Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates

Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update

GlobeNewswire

6 months ago

Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update

Merus to Present at Upcoming Investor Conferences

GlobeNewswire

6 months ago

Merus to Present at Upcoming Investor Conferences

Will Iovance Biotherapeutics (IOVA) Report Negative Earnings Next Week? What You Should Know

Zacks

7 months ago

Will Iovance Biotherapeutics (IOVA) Report Negative Earnings Next Week? What You Should Know

MT Newswires

7 months ago

Merus Says US FDA Grants Breakthrough Therapy Designation to Petosemtamab

Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma

GlobeNewswire

7 months ago

Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma

Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit

GlobeNewswire

7 months ago

Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit

MT Newswires

7 months ago

Piper Sandler Initiates Merus at Overweight With $84 Price Target

MT Newswires

7 months ago

Wells Fargo Initiates Merus at Overweight With $91 Price Target

New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer

GlobeNewswire

7 months ago

New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus N.V. (MRUS): The Biotech Stock with Biggest Upside Potential

Insider Monkey

8 months ago

Merus N.V. (MRUS): The Biotech Stock with Biggest Upside Potential

Companies Like Merus (NASDAQ:MRUS) Are In A Position To Invest In Growth

Simply Wall St.

8 months ago

Companies Like Merus (NASDAQ:MRUS) Are In A Position To Invest In Growth

MT Newswires

8 months ago

Merus, Biohaven Partner to Develop Bispecific Therapies for Cancers

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

GlobeNewswire

8 months ago

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

Jim Cramer Says Merus (MRUS) Still ‘Very Speculative’

Insider Monkey

8 months ago

Jim Cramer Says Merus (MRUS) Still ‘Very Speculative’

MT Newswires

9 months ago

Merus Reports First Person Dosed in Mid-Stage Petosemtamab Trial

Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC

GlobeNewswire

9 months ago

Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC

Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy

Insider Monkey

9 months ago

Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

GlobeNewswire

9 months ago

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus Scores Its First FDA Approval For Lung Cancer Drug

Benzinga

9 months ago

Merus Scores Its First FDA Approval For Lung Cancer Drug

Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers

Clinical Trials Arena

9 months ago

Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers

MT Newswires

9 months ago

Merus Gets US FDA Approval for Bizengri in Advanced Pancreatic, Lung Cancers

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

GlobeNewswire

9 months ago

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus price target lowered to $109 from $111 at Guggenheim

TipRanks

9 months ago

Merus price target lowered to $109 from $111 at Guggenheim

Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus' Pipeline

Benzinga

9 months ago

Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus' Pipeline

MT Newswires

9 months ago

Merus Licenses Potential Lung, Pancreatic Cancer Treatment to Partner Therapeutics

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

GlobeNewswire

9 months ago

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

GlobeNewswire

9 months ago

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus NV (MRUS): Among the Most Promising Cancer Stocks According to Hedge Funds

Insider Monkey

9 months ago

Merus NV (MRUS): Among the Most Promising Cancer Stocks According to Hedge Funds

PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...

GuruFocus.com

10 months ago

PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...

Is Merus N.V. (MRUS) Top Performing European Stock Heading into 2025?

Insider Monkey

10 months ago

Is Merus N.V. (MRUS) Top Performing European Stock Heading into 2025?

Merus to Present at Upcoming Investor Conferences

GlobeNewswire

10 months ago

Merus to Present at Upcoming Investor Conferences

MT Newswires

10 months ago

Merus Gets FDA Extension on Prescription Drug User Fee Act Goal Date for Zenocutuzumab to Feb. 4

Merus Receives FDA extension of PDUFA for zenocutuzumab

GlobeNewswire

10 months ago

Merus Receives FDA extension of PDUFA for zenocutuzumab

Merus Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

10 months ago

Merus Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

MT Newswires

10 months ago

Merus's Shares Dip After Reporting Wider-Than-Expected Q3 Net Loss

Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates

Zacks

10 months ago

Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates

Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update

GlobeNewswire

10 months ago

Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update

MT Newswires

10 months ago

UBS Initiates Merus With Buy Rating, $72 Price Target

Investing in Merus (NASDAQ:MRUS) five years ago would have delivered you a 227% gain

Simply Wall St.

a year ago

Investing in Merus (NASDAQ:MRUS) five years ago would have delivered you a 227% gain

MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains?

Zacks

a year ago

MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains?

Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC

GlobeNewswire

a year ago

Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC

TimesSquare Capital Management U.S. Small Cap Growth Strategy Established a Position in Merus N.V. (MRUS)

Insider Monkey

a year ago

TimesSquare Capital Management U.S. Small Cap Growth Strategy Established a Position in Merus N.V. (MRUS)

Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024

GlobeNewswire

a year ago

Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024

Merus NV (MRUS): Short Seller Sentiment is Bearish on This Cancer Stock

Insider Monkey

a year ago

Merus NV (MRUS): Short Seller Sentiment is Bearish on This Cancer Stock

Merus NV (MRUS): Top ADR Stock According to Hedge Funds

Insider Monkey

a year ago

Merus NV (MRUS): Top ADR Stock According to Hedge Funds

MT Newswires

a year ago

Merus Insider Sold Shares Worth $270,000, According to a Recent SEC Filing

We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate

Simply Wall St.

a year ago

We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate

Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference

GlobeNewswire

a year ago

Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference

Merus N.V. (MRUS) Reports Q2 Loss, Lags Revenue Estimates

Zacks

a year ago

Merus N.V. (MRUS) Reports Q2 Loss, Lags Revenue Estimates

Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update

GlobeNewswire

a year ago

Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update

Agenus (AGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Zacks

a year ago

Agenus (AGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

a year ago

Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC

GlobeNewswire

a year ago

Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC

Institutional investors control 69% of Merus N.V. (NASDAQ:MRUS) and were rewarded last week after stock increased 5.5%

Simply Wall St.

a year ago

Institutional investors control 69% of Merus N.V. (NASDAQ:MRUS) and were rewarded last week after stock increased 5.5%

MT Newswires

a year ago

Merus Begins Phase 2 Trial of Colorectal Cancer Drug Candidate

Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC

GlobeNewswire

a year ago

Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC

MT Newswires

a year ago

Sector Update: Health Care Stocks Retreat Late Afternoon

MT Newswires

a year ago

Merus Names New Chief Medical Officer

Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

GlobeNewswire

a year ago

Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

MT Newswires

a year ago

Stifel Nicolaus Adjusts Merus N.V Price Target to $99 From $90, Maintains Buy Rating

MT Newswires

a year ago

Merus Insider Sold Shares Worth $475,456, According to a Recent SEC Filing

MT Newswires

a year ago

BMO Capital Raises Price Target on Merus to $91 From $84, Maintains Outperform Rating

MT Newswires

a year ago

Canaccord Genuity Adjusts Price Target on Merus to $67 From $54, Maintains Buy Rating

MT Newswires

a year ago

Merus Says Target Tumors in Lung Cancer Patients Decrease in Size After MCLA-129 Treatment

Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting

GlobeNewswire

a year ago

Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting

MT Newswires

a year ago

Truist Securities Raises Price Target on Merus to $88 From $69, Maintains Buy Rating

Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting

GlobeNewswire

a year ago

Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting

MT Newswires

a year ago

Merus Prices $400.2 Million Public Share Offering

Share on Social Networks: